Metastatic breast cancer is complex, requiring holistic care and ongoing treatment, with varying prognosis depending on ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients ...

Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according ...

Her research seeks to answer a key question: Can exercise help slow or even prevent breast cancer progression? Morris recently spoke to Technology Networks about how her lab is trying to answer this.

Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...

Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...

NEW YORK - A Ludwig Cancer Research study has identified a key barrier to the efficacy of a promising combination of ...

Vepdegestrant did not improve progression-free survival broadly but saw improvements in one specific patient cohort. Arvinas’ ...